rss
J Clin Pathol 2006;59:537-541 doi:10.1136/jcp.2005.030544
  • Original article

Role of Epstein-Barr virus DNA measurement in plasma in the clinical management of nasopharyngeal carcinoma in a low risk area

  1. J S Kalpoe1,
  2. P B Douwes Dekker2,
  3. J H J M van Krieken3,
  4. R J Baatenburg de Jong2,
  5. A C M Kroes1
  1. 1Department of Medical Microbiology, Leiden University Medical Centre, Leiden, Netherlands
  2. 2Department of Otolaryngology and Head and Neck Surgery, Leiden University Medical Centre
  3. 3Department of Pathology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
  1. Correspondence to:
 Professor A C M Kroes
 Department of Medical Microbiology, E4-69, Leiden University Medical Centre, PO Box 9600, 2300 RC Leiden, Netherlands; A.C.M.Kroes{at}lumc.nl
  • Accepted 12 September 2005
  • Published Online First 17 February 2006

Abstract

Objective: To evaluate the role of quantitative measurement of Epstein-Barr virus (EBV) DNA in the clinical management of nasopharyngeal carcinoma (NPC) in a low tumour risk area (western Europe).

Methods: 22 consecutive Dutch NPC patients (11 europid) were studied. EBV DNA load in pretreatment and post-treatment plasma samples was determined. Three patients were also sampled at frequent intervals during treatment. RNA in situ hybridisation for the detection of EBV encoded RNAs (EBERs) was carried out on tumour biopsies of all cases.

Results: All patients with EBER positive NPC (20/22) showed a positive EBV DNA load in plasma at the time of diagnosis (median EBV DNA level, 4.1 log10 copies/ml). Patients with EBER negative NPC had no detectable EBV DNA in plasma. After treatment, complete remission was achieved in all cases and concurrently EBV DNA in plasma became undetectable in all patients. In the three longitudinally evaluated cases, EBV DNA load gradually declined towards undetectable levels within three weeks after start of treatment. Two patients developed a distant metastasis with concomitant increases in EBV viral load. In addition, one EBER positive patient developed an EBER negative metastasis in the neck during follow up and in this case EBV DNA load remained undetectable at the time of recurrence.

Conclusions: Plasma EBV DNA load measurement appears to be useful in a low tumour risk area. However, development of local recurrences may not always coincide with raised levels of EBV DNA.

Footnotes

    This Article

    1. Abstract
    2. Full text
    3. PDF
    4. All versions of this article:
      1. jcp.2005.030544v1
      2. 59/5/537 most recent

    Responses

    1. Submit a response
    2. No responses published

    Register for free content

    The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

    Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.